These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22978251)

  • 1. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
    Moysan E; Bastiat G; Benoit JP
    Mol Pharm; 2013 Feb; 10(2):430-44. PubMed ID: 22978251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacology of nucleoside analogues].
    Milano G; Chamorey AL; Thyss A
    Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs.
    Wang G; Chen H; Zhao D; Ding D; Sun M; Kou L; Luo C; Zhang D; Yi X; Dong J; Wang J; Liu X; He Z; Sun J
    J Med Chem; 2017 Mar; 60(6):2552-2561. PubMed ID: 28234466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
    Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
    Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
    Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
    Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
    Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
    J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
    Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
    J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
    Thompson BR; Shi J; Zhu HJ; Smith DE
    Biochem Pharmacol; 2020 Oct; 180():114127. PubMed ID: 32603666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
    Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
    J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
    Calvagno MG; Celia C; Paolino D; Cosco D; Iannone M; Castelli F; Doldo P; Frest M
    Curr Drug Deliv; 2007 Jan; 4(1):89-101. PubMed ID: 17269921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
    Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
    Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
    Alexander RL; Greene BT; Torti SV; Kucera GL
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):15-21. PubMed ID: 15789226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does saturable formation of gemcitabine triphosphate occur in patients?
    Tham LS; Wang LZ; Soo RA; Lee HS; Lee SC; Goh BC; Holford NH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):55-64. PubMed ID: 18305939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
    Wang Y; Wang G; Chen H; Sun Y; Sun M; Liu X; Jian W; He Z; Sun J
    Int J Pharm; 2020 Jan; 573():118718. PubMed ID: 31756441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
    Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
    Brusa P; Immordino ML; Rocco F; Cattel L
    Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.